Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
host | mouse |
isotype | IgG2a |
clonality | monoclonal |
concentration | concentrate, predilute |
applications | IHC |
reactivity | human |
available size | 0.1 mL, 0.5 mL, 1 mL concentrated, 7 mL prediluted |
mouse anti-Thrombomodulin/ CD141 monoclonal antibody (ZM105) 6380
$160.00 – $528.00
Antibody summary
- Mouse monoclonal to Thrombomodulin/ CD141
- Suitable for: Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
- Reacts with: Human
- Isotype:IgG2a
- Control: Mesothelioma
- Visualization: Cytoplasmic
- 0.1, 0.5, 1.0 mL concentrated, 7 mL prediluted
mouse anti-Thrombomodulin/ CD141 monoclonal antibody ZM105 6380
target relevance |
---|
Protein names Thrombomodulin (TM) (Fetomodulin) (CD antigen CD141) |
Mass 60329Da |
Function Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated. |
Subellular location Membrane; Single-pass type I membrane protein. |
Tissues Endothelial cells are unique in synthesizing thrombomodulin. |
Structure Interacts with ITGAL, ITGAM and ITGB2. |
Post-translational modification PTM: N-glycosylated.; PTM: The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains. |
Domain DOMAIN 31..169; /note="C-type lectin"; /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"; DOMAIN 241. |
Involvement in disease Thrombophilia due to thrombomodulin defect (THPH12) [MIM:614486]: A hemostatic disorder characterized by a tendency to thrombosis. Note=The disease may be caused by variants affecting the gene represented in this entry. The role of thrombomodulin in thrombosis is controversial. It is likely that genetic or environmental risk factors in addition to THBD variation are involved in the pathogenesis of venous thrombosis.; Hemolytic uremic syndrome, atypical, 6 (AHUS6) [MIM:612926]: An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype. |
Target Relevance information above includes information from UniProt accession: P07204 |
The UniProt Consortium |
Data
Human urothelial carcinoma stained with anti-Thrombomodulin antibody using peroxidase-conjugate and DAB chromogen. Note the cytoplasmic staining of tumor cells. |
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.pmid | title | authors | citation |
---|
Protocols
relevant to this product |
---|
IHC |
Documents
# | |||
---|---|---|---|
Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information. |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.